Office Action Predictor
Last updated: April 15, 2026
Application No. 18/206,316

CONTINUOUS METHOD FOR PREPARING TRICYANOIMIDAZOLE

Final Rejection §112
Filed
Jun 06, 2023
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Uchicago Argonne, LLC
OA Round
2 (Final)
78%
Grant Probability
Favorable
3-4
OA Rounds
2y 3m
To Grant
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
1410 granted / 1810 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
29 currently pending
Career history
1839
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
7.1%
-32.9% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
52.2%
+12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1810 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-15 and 17-21 are currently pending in the instant application. Applicants have amended claims 1, 17 and 18, cancelled claim 16 and added new claim 21 in an amendment filed on November 6, 2025. Claims 1-15 and 17-20 are rejected and claim 21 is considered allowable in this Office Action. I. Response to Arguments/Remarks Applicants’ amendment, filed on November 6, 2025, has overcome the rejection of claims 1-5, 9-13 and 19 under 35 USC 103 as being unpatentable over Bitner-Michalska, et al. (WO 2016/203390 A1) and the objection of claims 6-8, 14-18 and 20 as being dependent upon a rejected based claim. The above rejection and objection have been withdrawn. II. Rejection(s) Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-15 and 17-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claim 1 contains the limitation that the process contains step (b) which is “a step selected from (b1) and (b2)”. The broadest interpretation of this limitation is that the process can either include step (b1) or (b2) but does not have to include both. Applicants have amended step (b1) to include the limitation “further comprising a first inorganic base” and also have amended step (b2) to include the limitation “and a second inorganic base”. The broadest interpretation of the limitation in step (b2) is that if there is a “second inorganic base” then it is assumed that there is a “first inorganic base” earlier in the process. The issue is that according to the language in claim 1, step (b1) is not required for this claimed process. So if step (b1) is not required and is not present then where is the “first inorganic base” present during the claimed process. It is unclear if there is another inorganic base” being used in step (a) that is not mentioned or are Applicants intending that both step (b1) and (b2) are present in the reaction. Because of this clarity issue with the newly amended claim limitation, the claims are considered indefinite. To overcome the rejection, Applicants are suggested to, for example, amend claim 1 to delete the terms “first” and “second” in front of the “inorganic base” so that the limitation is no longer unclear. III. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 06, 2023
Application Filed
Sep 26, 2025
Non-Final Rejection — §112
Oct 22, 2025
Response after Non-Final Action
Oct 22, 2025
Response Filed
Nov 06, 2025
Response Filed
Mar 15, 2026
Final Rejection — §112
Apr 08, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594265
METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3
2y 5m to grant Granted Apr 07, 2026
Patent 12595231
NOVEL CRYSTALLINE SALT FORMS OF MESEMBRINE
2y 5m to grant Granted Apr 07, 2026
Patent 12590047
METHOD FOR PRODUCING FLUORINE-CONTAINING OLEFIN
2y 5m to grant Granted Mar 31, 2026
Patent 12583818
NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12576396
POLYNORBORNENE/CARBON BLACK-CROSS-LINKED THREE-DIMENSIONAL NETWORK-IMMOBILIZED COPPER/GOLD (PNBI/CB-Cu/Au) NANOCATALYST, AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.4%)
2y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 1810 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month